NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$14.19 USD
+1.45 (11.38%)
Updated May 2, 2024 04:00 PM ET
After-Market: $14.18 -0.01 (-0.07%) 4:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVCR 14.19 +1.45(11.38%)
Will NVCR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NVCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVCR
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
NVCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
Cencora (COR) to Report Q2 Earnings: What's in the Cards?
Other News for NVCR
Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024
NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript
NovoCure Limited 2024 Q1 - Results - Earnings Call Presentation
BioPharma Credit agrees USD400 million loan for oncology firm Novacure